Psyence Biomedical Ltd. (PBM) Net Income towards Common Stockholders (2023 - 2025)

Psyence Biomedical (PBM) has reported Net Income towards Common Stockholders for 3 consecutive years, with -$1.5 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Net Income towards Common Stockholders fell 230.18% year-over-year to -$1.5 million; the TTM figure through Mar 2026 stood at -$348878.6 (up 83.22% YoY), while the FY2026 annual figure was -$6.2 million, down 70.34% from the prior year.
• Net Income towards Common Stockholders came in at -$1.5 million for Q3 2025 at Psyence Biomedical, down from $1.2 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $1.2 million in Q3 2024, with the low at -$3.2 million in Q1 2023.
• Average Net Income towards Common Stockholders over 3 years is -$1.2 million, with a median of -$1.5 million recorded in 2025.
• The largest YoY upside for Net Income towards Common Stockholders was 230.18% in 2025 against a maximum downside of 230.18% in 2025.
• Year by year, Net Income towards Common Stockholders stood at -$3.2 million in 2023, then soared by 135.74% to $1.2 million in 2024, then plunged by 230.18% to -$1.5 million in 2025.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$1.5 million, $1.2 million, and -$3.2 million for Q3 2025, Q3 2024, and Q1 2023 respectively.